The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BC3195, a novel ADC targeting cadherin-3 (CDH3): Updated results of a first-in-human phase I study in patients with advanced solid malignancies.
 
Haiyan Tu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Tao Qin
No Relationships to Disclose
 
Hai-jun Guo
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Sheng Wang
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Li-qin Zhang
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Xiang-yun Ye
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Yong-Jiang Hei
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Yiwei Wang
Employment - Biocity Biopharmaceutics Co. Ltd, Wuxi, China.
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)